Biote Corp. Projects Significant EBITDA Decline for 2026 Amidst Large Share Repurchases
BTMD sits 25% above its 52-week low of $1.27.
Summary
Biote Corp. released an investor presentation detailing 2026 guidance, which includes a significant projected decline in Adjusted EBITDA, alongside a substantial $18.5 million share repurchase completed in January 2026.
Key Events · Financing and Capital Events · BTMD
-
2026 Financial Guidance Issued
Biote Corp. projects 2026 revenue to be above $190 million and Adjusted EBITDA to be above $38 million.
-
Significant Projected EBITDA Decline
The 2026 Adjusted EBITDA guidance of above $38 million represents a substantial decrease from $53.5 million reported in 2025.
-
Large Share Repurchase Completed
The company paid $18.5 million in January 2026 to repurchase 6.1 million shares of Class V voting stock, following previous repurchases of 5.5 million shares for $25.1 million and 2.8 million shares for $12.5 million.
-
Ongoing Share Repurchase Program
An $11.0 million balance remains in the Class A common stock repurchase program, with $3.4 million purchased in 2025.
Analysis · BTMD · Life Sciences
This 8-K filing, which includes an investor presentation, provides critical updates on biote Corp.'s financial outlook and capital allocation strategy. The company projects a significant decline in Adjusted EBITDA for 2026 compared to 2025, indicating operational headwinds. However, this comes alongside a substantial $18.5 million share repurchase completed in January 2026, representing a very large portion of the company's market capitalization. This aggressive capital return signals strong management confidence in the company's long-term value despite the weaker profitability outlook. Investors will need to carefully weigh the implications of the projected operational decline against the shareholder-friendly capital allocation decisions and strategic moves towards vertical integration.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BTMD was trading at $1.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.4M. The 52-week trading range was $1.27 to $4.75. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.